New hope for young cancer patients: drug combo targets relapsed solid tumors

This study tests a combination of drugs (liposomal mitoxantrone, capecitabine, and anlotinib) in children, adolescents, and young adults whose solid tumors have returned or not responded to previous treatments. The goal is to see if this regimen can shrink tumors or stop them from growing. Participants will receive up to 6 cycles of treatment and be closely monitored for side effects and tumor response.